TRACON Pharmaceuticals, Inc. (TCON)
| Market Cap | 44.73M |
| Revenue (ttm) | 346,000 |
| Net Income (ttm) | -25.27M |
| Shares Out | 19.45M |
| EPS (ttm) | -1.60 |
| PE Ratio | n/a |
| Forward PE | n/a |
| Dividend | n/a |
| Ex-Dividend Date | n/a |
| Volume | 91,020 |
| Open | 2.36 |
| Previous Close | 2.36 |
| Day's Range | 2.28 - 2.47 |
| 52-Week Range | 2.18 - 11.76 |
| Beta | 1.77 |
| Analysts | Buy |
| Price Target | 11.86 (+415.7%) |
| Earnings Date | Nov 3, 2021 |
About TCON
TRACON Pharmaceuticals, Inc., a clinical stage biopharmaceutical company, focuses on the development and commercialization of therapeutics for cancer and age-related macular degeneration and fibrotic diseases in the United States. Its lead clinical stage product include envafolimab (KN035), an investigational PD-L1 single-domain antibody for the treatment of soft tissue sarcoma. The company's clinical stage products also include TRC102, which is a small molecule that is in Phase II clinical trial for the treatment of mesothelioma, Phase I clini...
Financial Performance
Financial StatementsAnalyst Forecast
According to 6 analysts, the average rating for TCON stock is "Buy." The 12-month stock price forecast is 11.86, which is an increase of 415.65% from the latest price.
News
TRACON Pharmaceuticals to Present at the H.C. Wainwright BIOCONNECT Virtual Conference
SAN DIEGO, Jan. 05, 2022 (GLOBE NEWSWIRE) -- TRACON Pharmaceuticals (NASDAQ: TCON), a clinical stage biopharmaceutical company focused on the development and commercialization of novel targeted cancer t...
TRACON Pharmaceuticals Announces Positive Results from the Independent Data Monitoring Committee Review of Interim Sa...
Pre-specified Interim Analysis Concluded with Recommendation to Continue the ENVASARC Trial
TRACON Pharmaceuticals Reports Regulatory Approval of Envafolimab in China
First Approval of a Subcutaneously Administered Checkpoint Inhibitor
5 Stocks Insiders Are Still Buying (Even As Others Cash Out)
Insider sales are generally a sign the market is about to drop, but not everyone's selling. Here are five companies with insider buying.
TRACON Pharmaceuticals to Present at the Jefferies London Virtual Healthcare Conference
SAN DIEGO, Nov. 11, 2021 (GLOBE NEWSWIRE) -- TRACON Pharmaceuticals (NASDAQ: TCON), a clinical stage biopharmaceutical company focused on the development and commercialization of novel targeted cancer t...
TRACON Pharmaceuticals Reports Third Quarter 2021 Financial Results and Provides Corporate Update
SAN DIEGO, Nov. 03, 2021 (GLOBE NEWSWIRE) -- TRACON Pharmaceuticals (NASDAQ:TCON), a clinical stage biopharmaceutical company focused on the development and commercialization of novel targeted cancer th...
TRACON to Report Third Quarter 2021 Financial Results and Company Highlights on November 3, 2021
SAN DIEGO, Oct. 27, 2021 (GLOBE NEWSWIRE) -- TRACON Pharmaceuticals (NASDAQ:TCON), a clinical stage biopharmaceutical company focused on the development and commercialization of novel targeted cancer th...
TRACON Pharmaceuticals Announces Appointment of Carol Lam to its Board of Directors
SAN DIEGO, Oct. 13, 2021 (GLOBE NEWSWIRE) -- TRACON Pharmaceuticals (NASDAQ:TCON), a clinical stage biopharmaceutical company focused on the development and commercialization of novel targeted therapeut...
TRACON Pharmaceuticals and Eucure Biopharma, a Subsidiary of Biocytogen, Announce Partnership for Development of Clin...
YH001 is a potential best-in-class CTLA-4 antibody with enhanced ADCC and CDC effector functions
TRACON Pharmaceuticals to Present at the Oppenheimer Fall Healthcare Life Sciences and MedTech Summit
SAN DIEGO, Sept. 13, 2021 (GLOBE NEWSWIRE) -- TRACON Pharmaceuticals (NASDAQ: TCON), a clinical stage biopharmaceutical company focused on the development and commercialization of novel targeted cancer ...
TRACON Pharmaceuticals to Present at the H.C. Wainwright 23rd Annual Global Investment Conference
SAN DIEGO, Sept. 07, 2021 (GLOBE NEWSWIRE) -- TRACON Pharmaceuticals (NASDAQ: TCON), a clinical stage biopharmaceutical company focused on the development and commercialization of novel targeted cancer ...
TRACON Pharmaceuticals on the Fast Track for Sarcoma Injection Treatments
Sarcoma is not one of the many cancers that reaches top billing in the discussion of cancer research. The cancer starts in tissues like bone, muscle or soft tissue and affects a relatively small, 12,00...
TRACON Pharmaceuticals to Present at the Wells Fargo Virtual Healthcare Conference
SAN DIEGO, Sept. 02, 2021 (GLOBE NEWSWIRE) -- TRACON Pharmaceuticals (NASDAQ: TCON), a clinical stage biopharmaceutical company focused on the development and commercialization of novel targeted cancer ...
TRACON Pharmaceuticals Reports Second Quarter 2021 Financial Results and Provides Corporate Update
SAN DIEGO, Aug. 11, 2021 (GLOBE NEWSWIRE) -- TRACON Pharmaceuticals (NASDAQ:TCON), a clinical stage biopharmaceutical company focused on the development and commercialization of novel targeted cancer th...
TRACON Pharmaceuticals Announces Results of Second Independent Data Monitoring Committee Review of Safety Data from E...
- Trial to Continue as Planned - Trial to Continue as Planned
TRACON Pharmaceuticals to Present at the BTIG Virtual Biotechnology Conference
SAN DIEGO, Aug. 03, 2021 (GLOBE NEWSWIRE) -- TRACON Pharmaceuticals (NASDAQ: TCON), a clinical stage biopharmaceutical company focused on the development and commercialization of novel targeted cancer t...
TRACON to Report Second Quarter 2021 Financial Results and Company Highlights on August 11, 2021
SAN DIEGO, July 28, 2021 (GLOBE NEWSWIRE) -- TRACON Pharmaceuticals (NASDAQ:TCON), a clinical stage biopharmaceutical company focused on the development and commercialization of novel targeted cancer th...
TRACON Pharmaceuticals Increases Previously Announced Bought Deal Offering of Common Stock to $15.0 Million
SAN DIEGO, July 21, 2021 (GLOBE NEWSWIRE) -- TRACON Pharmaceuticals (NASDAQ: TCON) (“TRACON” or the “Company”), a clinical stage biopharmaceutical company focused on the development and commercializatio...
TRACON Pharmaceuticals Announces $10 Million Bought Deal Offering of Common Stock
SAN DIEGO, July 21, 2021 (GLOBE NEWSWIRE) -- TRACON Pharmaceuticals (NASDAQ: TCON) (“TRACON” or the “Company”), a clinical stage biopharmaceutical company focused on the development and commercializatio...
TRACON Pharmaceuticals Announces Appointment of Brenda Marczi, PharmD, as Senior Vice President, Regulatory Affairs, ...
SAN DIEGO, July 20, 2021 (GLOBE NEWSWIRE) -- TRACON Pharmaceuticals (NASDAQ: TCON), a clinical stage biopharmaceutical company focused on the development and commercialization of novel targeted cancer t...
TRACON Pharmaceuticals Announces Appointment of Ya Huang as Executive Director of Statistical Programming and Grantin...
SAN DIEGO, June 30, 2021 (GLOBE NEWSWIRE) -- TRACON Pharmaceuticals (NASDAQ: TCON), a clinical stage biopharmaceutical company focused on the development and commercialization of novel targeted cancer t...
TRACON Pharmaceuticals Announces Orphan Drug Designation for Envafolimab in Soft Tissue Sarcoma
Application Included Clinical Trial Data from Soft Tissue Sarcoma Patients Treated with Envafolimab in Phase 1 Trials
TRACON Pharmaceuticals Presents Data from a Phase 1 Study of Uliledlimab (TJ004309) and Tecentriq® (Atezolizumab) at ...
SAN DIEGO, June 04, 2021 (GLOBE NEWSWIRE) -- TRACON Pharmaceuticals (NASDAQ:TCON), a clinical stage biopharmaceutical company focused on the development and commercialization of novel targeted therapeut...
TRACON Pharmaceuticals Announces Results of Independent Data Monitoring Committee Review of Safety Data from ENVASARC...
Trial to Continue as Planned Trial to Continue as Planned
TRACON Pharmaceuticals to Present at the Jefferies Virtual Healthcare Conference
SAN DIEGO, May 25, 2021 (GLOBE NEWSWIRE) -- TRACON Pharmaceuticals (NASDAQ: TCON), a clinical stage biopharmaceutical company focused on the development and commercialization of novel targeted cancer th...